ReviewChinese medicine2024
Pharmacological properties of Polygonatum and its active ingredients for the prevention and treatment of cardiovascular diseases.
Review in Chinese medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 34 citations in OpenAlex.
- Natural product therapy in diabetic kidney disease: emerging multiomics-mediated signalling pathway and molecular target.Chinese medicine · 2026Review
- First Report and Biological Characterization ofPlants (Basel, Switzerland) · 2026Article
- Research on the ultrasonic-assisted extraction, purification, structural characterization, and anti- glycolipid metabolic disorder (anti-GLMD) activity and mechanism of polysaccharide from Dryopteridis crassirhizomatis Rhizoma.Ultrasonics sonochemistry · 2026Article
- The Downward Floral Orientation inEcology and evolution · 2026Article
- Cardioprotective potential of Maharishi Amrit Kalash: a scoping review of evidence from experimental and clinical studies.Frontiers in pharmacology · 2026Review
- Study on the Anti-fatigue Effects of Polysaccharides from Erjing Formula.Current pharmaceutical biotechnology · 2026Article
- Mechanistic insights of hypoglycemic components fromFrontiers in endocrinology · 2026Article
- Liriodendrin alleviates myocardial ischemia‑reperfusion injury via partially attenuating apoptosis, inflammation and mitochondria damage in rats.International journal of molecular medicine · 2025Article
- A Systematic Method for the Identification of Oligosaccharide Constituents inMolecules (Basel, Switzerland) · 2025Article
- Integrative Metabolome and Transcriptome Analyses Reveal the Effects of Plucking Flower on Polysaccharide Accumulation in the Rhizomes ofMolecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Despite continued advances in prevention and treatment strategies, cardiovascular diseases (CVDs) remain the leading cause of death worldwide, and more effective therapeutic methods are urgently needed. Polygonatum is a traditional Chinese herbal medicine with a variety of pharmacological applications and biological activities, such as antioxidant activity, anti-inflammation, antibacterial effect, immune-enhancing effect, glucose regulation, lipid-lowering and anti-atherosclerotic effects, treatment of diabetes and anticancer effect. There has also been more and more evidence to support the cardioprotective effect of Polygonatum in recent years. However, up to now, there has been a lack of comprehensive studies on the active ingredients and their pharmacotoxicological effects related to cardiovascular diseases. Therefore, the main active components of Polygonatum (including Polysaccharides, Flavonoids, Saponins) and their biological activities were firstly reviewed in this paper. Furthermore, we summarized the pharmacological effects of Polygonatum's active components in preventing and treating CVDs, and its relevant toxicological investigations. Finally, we emphasize the potential of Polygonatum in the prevention and treatment of CVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.